Systemic sclerosis & Raynaud's
The prognostic power of anti-topoisomerase I and anti-centromere antibodies in systemic sclerosis - A systematic review of the literature
Authors' conclusion
In conclusion, there is little sound evidence to support an independent prognostic value of ATA and ACA for mortality in SSc. ATA is associated with future ILD development, while ACA decreases the risk of ILD development.
Study context
- Population
- Longitudinal systemic sclerosis (SSc) studies reporting the prognostic value of ATA and anti-centromere antibodies (ACA) for survival or disease complications43 studies
- Comparison
- ATA and ACA positivity as prognostic factors for survival and disease complications in SSc
- Outcome
- Prognostic value of ATA and ACA for survival or disease complications
Methodological detailsQUIPS risk of bias tool, studies with <30 events, <30 ACA or ATA positive patients, or moderate to high risk of bias excluded, Mean baseline disease duration 1 to 12 years; follow-up 1 to 18.1 years
- QUIPS risk of bias tool
- Studies with <30 events, <30 ACA or ATA positive patients, or moderate to high risk of bias excluded
- Mean baseline disease duration 1 to 12 years; follow-up 1 to 18.1 years
Pooled result
As reported in the abstract
ATA prognostic for mortality
1 of 21 studies
Higher survival rates for ACA positive patients
5 of 19 studies
ATA associated with future ILD development
4 of 7 studies
ACA associated with lower risk of ILD development
3 of 4 studies
Further pooled results
Other disease outcomes
- Data are scarce
Original publication
The prognostic power of anti-topoisomerase I and anti-centromere antibodies in systemic sclerosis - A systematic review of the literature. Semin Arthritis Rheum. Published 22 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →